Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer
1987
: Turisteron proves to be a highly effective, poor in side effects, orally applicable estrogen preparation for the hormone therapy of the carcinoma of the prostate under the conditions of the routine practice. The cumulative 5-year survival rates of 197 patients observed of all categories of tumours (T1-4NxM0-1) were 66 +/- 10% and were depending upon the local growth of the tumour and upon the degree of metastasation between 81 +/- 18% and 47 +/- 42%. A discontinuation of the therapy due to strong side effects was necessary only in 4 cases (2.07%).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI